Abstract
The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recognized that B lymphocytes play a role in the pathogenesis of many autoimmune diseases, though the extent and contribution is a matter of debate and active investigation. There is emerging data to suggest that both antibody-dependent and independent mechanisms contribute to disease pathogenesis. However, given the heterogeneous nature of autoimmune diseases, and the varied responses to B lymphocyte reduction, the role of B lymphocytes is likely disease-specific. The two clinical trials discussed in this review demonstrate remarkable consistency in the ability of B cell reduction to ameliorate the clinical manifestations of rheumatoid arthritis with minimal toxicity. B lymphocyte targeted approaches to autoimmune disease in general, and RA specifically, will not only provide an effective and potentially less toxic alternative treatment option, but also allow for a better understanding of the pathogenesis of these complex and morbid diseases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 521-527 |
| Number of pages | 7 |
| Journal | Hematology |
| Volume | 10 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2005 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
B cell reductive therapy in the treatment of autoimmune diseases : A focus on monoclonal antibody treatment of rheumatoid arthritis. / Tuscano, Joseph; Martin, Shiloh; Song, Kyle; Wun, Theodore.
In: Hematology, Vol. 10, No. 6, 12.2005, p. 521-527.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - B cell reductive therapy in the treatment of autoimmune diseases
T2 - A focus on monoclonal antibody treatment of rheumatoid arthritis
AU - Tuscano, Joseph
AU - Martin, Shiloh
AU - Song, Kyle
AU - Wun, Theodore
PY - 2005/12
Y1 - 2005/12
N2 - The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recognized that B lymphocytes play a role in the pathogenesis of many autoimmune diseases, though the extent and contribution is a matter of debate and active investigation. There is emerging data to suggest that both antibody-dependent and independent mechanisms contribute to disease pathogenesis. However, given the heterogeneous nature of autoimmune diseases, and the varied responses to B lymphocyte reduction, the role of B lymphocytes is likely disease-specific. The two clinical trials discussed in this review demonstrate remarkable consistency in the ability of B cell reduction to ameliorate the clinical manifestations of rheumatoid arthritis with minimal toxicity. B lymphocyte targeted approaches to autoimmune disease in general, and RA specifically, will not only provide an effective and potentially less toxic alternative treatment option, but also allow for a better understanding of the pathogenesis of these complex and morbid diseases.
AB - The therapeutic approach to patients with autoimmune disorders is in the midst of a dramatic change. Monoclonal antibody technology has allowed us to dissect and now manipulate the human immune system with greater precision. It is now widely recognized that B lymphocytes play a role in the pathogenesis of many autoimmune diseases, though the extent and contribution is a matter of debate and active investigation. There is emerging data to suggest that both antibody-dependent and independent mechanisms contribute to disease pathogenesis. However, given the heterogeneous nature of autoimmune diseases, and the varied responses to B lymphocyte reduction, the role of B lymphocytes is likely disease-specific. The two clinical trials discussed in this review demonstrate remarkable consistency in the ability of B cell reduction to ameliorate the clinical manifestations of rheumatoid arthritis with minimal toxicity. B lymphocyte targeted approaches to autoimmune disease in general, and RA specifically, will not only provide an effective and potentially less toxic alternative treatment option, but also allow for a better understanding of the pathogenesis of these complex and morbid diseases.
UR - http://www.scopus.com/inward/record.url?scp=31144454851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31144454851&partnerID=8YFLogxK
U2 - 10.1080/10245330500155424
DO - 10.1080/10245330500155424
M3 - Article
C2 - 16321818
AN - SCOPUS:31144454851
VL - 10
SP - 521
EP - 527
JO - Hematology
JF - Hematology
SN - 1024-5340
IS - 6
ER -